Back to today’s briefing

Story perspectives

GSK Reports Strong Q1, Eyes Growth Amid Tariff Risks

5/2/2025

47 3

Summary

Story summary

GSK reports robust first-quarter results with £7.52 billion turnover and 44.9p core profit per share.
CEO Emma Walmsley highlights AI and supply chain strategies to counter potential U.S. pharmaceutical tariffs.
GSK projects a positive outlook with 3-5% turnover growth anticipated by 2025.
AstraZeneca is relocating production to the U.S. to minimize tariff risks, while Pfizer remains cautious about U.S. investments.

History

Historical Context

GSK's current focus on AI and supply chain strategies echoes the pharmaceutical industry's historical responses to regulatory pressures. In 2012, GSK faced a $3 billion settlement for illegal practices. This past scrutiny now shapes their proactive measures against potential U.S. tariffs, reflecting a trend of adapting to market challenges.

1 of 2

Story summary

GSK reports robust first-quarter results with £7.52 billion turnover and 44.9p core profit per share.
CEO Emma Walmsley highlights AI and supply chain strategies to counter potential U.S. pharmaceutical tariffs.
GSK projects a positive outlook with 3-5% turnover growth anticipated by 2025.
AstraZeneca is relocating production to the U.S. to minimize tariff risks, while Pfizer remains cautious about U.S. investments.

1 / 2